



Public Health Crisis Response Cooperative Agreement: Mpox Response Funding

January 19, 2023

Dr. Jonathan Mermin

Incident Manager, CDC Multi-National Mpox Response &
Director, National Center for HIV/AIDS,
Viral Hepatitis, STD, and TB Prevention

Ted Castellanos, MPH

Deputy Branch Chief, Division of STD Prevention (DSTDP)
Program Development and Evaluation Branch (PDEB)

Overview of Presentation


- Opening Remarks from CDC's Mpox Response Incident Commander
- Purpose of Awards
- Eligibility and Funding
- Activities
- Budget Narrative and Work Plan Submission
- Performance Measures

OPENING REMARKS

Dr. Jonathan Mermin

Mpox epidemic curve

Official Case Count: 30,000




Data from recent days, shown in lighter colors, are not finalized and subject to change.

Total JYNNEOS Vaccine Doses Administered and Reported to CDC (As of 01/10/2023 at 4:00AM ET)



1,165,213 doses administered a reported to CDC since May 20, 2022



Source: CDC Immunization Data Lake. Data submitted as of January 10, 2023, 4:00 am ET.

Data are Provisional Until Officially Released by the CDC - For Internal Use Only (FIUO) - For Official Use Only (FOUO) - Sensitive But Unclassified (SBU) - Not for Further Distribution

Purpose Of Awards

CDC has activated CDC-RFA-TP22-2201: Public Health Crisis Response Cooperative Agreement

- Awards are intended to address urgent needs and to implement mpox response related activities including efforts to increase vaccine accessibility and uptake, case and cluster investigation, surveillance, testing, communication, education, and outreach
- Round 2 assists jurisdictions in responding to remaining cases of mpox, preventing future outbreaks by increasing vaccine accessibility, demand, and uptake, specifically among the populations recommended to receive vaccine, and strengthening capabilities to prepare for, and respond to reintroduction of cases of mpox.

Purpose Of Awards

- All states and jurisdictions are included in Round 2 of funding to ensure equitable efforts to increase vaccination coverage among populations at risk of mpox exposure are established, especially those that aim to reduce mpox vaccination disparities, and that state health departments are prepared to respond to future outbreaks of mpox cases

ROUND 2 – ELIGIBILITY AND FUNDING

TED CASTELLANOS, MPH

Mpox Crisis Response Award Eligibility

- Round 2
 - Tier 1 (Already awarded)
 - States (reporting 45+) and Localities (reporting 30+) mpox cases in October 2022
 - All other state jurisdictions,
 - District of Columbia
 - Puerto Rico
- Funding Formula
 - Round 2 - additional \$17.50 per eligible population estimate
 - Round 2 (excluding Tier 1)
 - \$150,000 Base

ACTIVITIES

Coordination of Activities

- Activities will address urgent mpox response needs that span across public health programs
- Specifically, CDC expects recipients to coordinate response activities across programs including immunization, STI/HIV, communicable disease, and emergency preparedness and response

Required Activities

- Create a work group to manage activities
- Increase vaccine accessibility and uptake
 - Examples include mobile clinics; outreach; events; education; ensconcing vaccination in HIV, STI, and other clinics; and addressing vaccine hesitancy
 - Incorporating health equity into vaccination strategy and implementation
 - Implementing communication strategies via social media and websites
 - Timely collection, entry, and reporting of all mpox vaccine administration data (required for all states, New York City, and Philadelphia only)

Required Activities

- Sustain or expand ongoing engagement of community members affected by the current mpox outbreak to inform priorities and collaborate in response activities
- Timely, effective case and cluster investigation, including outreach to contacts and social networks of people with mpox and collaboration with disease intervention specialists (DIS) as appropriate.

Required Activities

- Timely collection, entry, and reporting of all mpox case surveillance data to CDC, including data on race/ethnicity, gender identity, **vaccination status**, date, and route of administration, and exposure risks (required for all states and New York City only).
 - Where possible, jurisdictions are highly encouraged to develop automated linkages or regularly scheduled linking processes between their mpox case surveillance system and IIS systems to include the most accurate information on mpox vaccination status and dates on mpox case surveillance databases.

Other Allowable Activities

- Implement creative approaches to saturate networks experiencing mpox transmission with vaccination and other relevant services, including but not limited to incentivized, network-based recruiting
 - Recipients are encouraged to engage (and possibly fund) community-based organizations to conduct vaccine events and outreach among those most at risk (for example, within bath houses and sex venues, circuit parties, the house and ball community events)
- Gather qualitative and quantitative information from people with mpox to understand gaps in services that need to be addressed to interrupt transmission

Other Allowable Activities

- Increase accessibility of, timeliness of, and equitable access to mpox testing and, when needed, treatment, including through education of providers who are well-positioned to deliver testing and treatment to those who need them the most
- Initiate planning to transition mpox activities to become a routine component of sexual health and HIV clinical care with public health monitoring

Other Allowable Activities

- Collect and shipping specimens to facilitate monitoring for changes in the virus and for evidence of resistance to available therapeutics
- Recruitment and enrollment of mpox cases and at-risk persons into CDC multi-site evaluation to evaluate JYNNEOS vaccine effectiveness and duration of protection
- Other mpox response-related activities not stated above will be considered

BUDGET NARRATIVE AND WORK PLAN

Budget Narrative and Work Plan

- Budget narratives and work plans are due 03/06/2023
 - Work plans must include planned activities and performance metrics
 - Budget narratives:
 - Must propose funding by direct cost budget categories
 - Should identify funding to support local and community-based organizations (CBO) if applicable

Budget Narrative and Work Plan Submission

- Official Submission
 - Develop in REDCap
 - Upon completion in REDCap, PDF Budget Summary & Work Plan
 - PDF documents submitted to Grants Solutions
- If requesting any pre-award expenditures from December 1 through start of budget period:
 - Clearly identify in budget submission and provide a justification explaining how these expenditures support the activities in the guidance

Budget Narrative and Work Plan Submission

- Staff access To REDCap – submit information below via email to Tracey Hardy (tjh0@cdc.gov) as soon as possible
 - Name:
 - Jurisdiction/department:
 - Email:
 - Does the user currently have access to Secure Access Management Service (SAMS)?
 - Does the user currently have access to the CDC REDCap Environment?
 - If unsure about the User’s access to SAMS/CDC REDCap Env., just enter “Unsure”

PERFORMANCE MEASURES

Performance Measures

- Purpose
 - Understand the context and assess the extent to which strategies and activities are being implemented as expected
 - Support continuous program and system improvement
 - Improve overall project performance
- Measures correspond to required and allowable activities
 - Description of activities and outcomes
- Data collection
 - Reporting through CDC REDCap
 - CDC Immunization Data Lake

Performance Measures: Next Steps

- Frequency of reporting
 - Quarterly: first report due May 2023
 - Immunization (CDC Immunization Data Lake) and case data in real time
- CDC evaluation team will provide technical assistance for data entry and reporting
 - February 2023 webinar will provide overview of the process and required data elements
 - Office hours for first reporting period

Thank you for attending today's webinar

Slides will be made available at

<https://www.cdc.gov/cpr/readiness/funding/index.htm>

Additional questions can be directed to

DSLRCrisisCoAg@cdc.gov

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

